Biocon Ltd., Asia's premier biopharmaceutical company, is committed to ensure a global right to healthcare by addressing the worldwide need for safe, effective and affordable biotherapeutics. We have harnessed the power of biotechnology through affordable innovation to enhance access to new and differentiated therapies for diseases that are chronic, where medical needs are largely unmet.
The Company is a pioneer in bringing the benefit of high quality, yet affordable, novel biologics and biosimilars to patients in India and other emerging markets. Today, we are India's largest and fully-integrated biopharmaceutical company that develops, manufactures and supplies advanced, life-saving biopharmaceuticals for diabetes, cancer and autoimmune conditions at price points that make them affordable and thus accessible.
As an innovation-led organization focused on providing affordable access, we have leveraged our inherent strengths in advanced science to develop, manufacture and deliver a rich portfolio of small molecules APIs & formulations and complex biologics - both novels and biosimilars - including monoclonal antibodies (MAbs), rh-Insulin and insulin analogs.
Our global scale capacities for manufacturing high quality, affordable biologics have positioned us as the world's fourth largest insulins producer, enabling us to address the growing needs of diabetes patients across the globe. As one of the leading oncology companies in India, we have brought safe, efficacious and affordable medicines for cancer to cater to the needs of patients, caregivers and medical practitioners in the country.
As India's largest domestic branded biologics company, we have taken key products like INSUGEN®(rh-insulin), BASALOG® (Glargine), CANMAb™ (Trastuzumab), BIOMAb-EGFR™ (Nimotuzumab) and ALZUMAb™ (Itolizumab), a ‘first in class’ anti-CD6 monoclonal antibody, from discovery to commercialization.
Seeking Global Leadership
Our value proposition, built around differentiation and scale, has enabled us to seek global leadership to provide access to affordable biopharmaceuticals for patients, partners and healthcare systems across the globe. Our patient-centric approach and commitment to world-class quality have earned the trust of partners, doctors, patients, care givers and healthcare ecosystems around the world. Our aim over the next 10 years is to provide our insulin products to 'one in five' diabetes patients in need of insulin-based therapy anywhere in the world. Biocon is poised to emerge as a relevant global enterprise, delivering cutting-edge innovation that is affordable, available and accessible.
To address the global healthcare challenges associated with non-communicable diseases such as cancer and diabetes we have invested in cutting-edge science, global manufacturing scale and key international collaborations. In this endeavor, we have created a highly cross-functional matrix focused on products, processes and people to reliably and consistently develop and deliver differentiated products. We have consistently been among the pharma companies in India with the highest investments in research and development. We have made long-term investments in creating 'best-in-class' complex biologics manufacturing capabilities. We have rapidly moved up the pharmaceutical value chain from small molecules to recombinant proteins to antibodies. We have leveraged India's value advantage of unmatched scientific talent and cost-competitive manufacturing to deliver scale, speed and quality. Over time, we have emerged as a highly innovative biopharmaceuticals enterprise that has benefited millions of patients in over 100 countries.
Commitment to Quality
Our state-of-the-art manufacturing facilities - both mammalian and microbial - designed to conform to the most stringent cGMP guidelines, comply with international regulatory standards and meet client requirements worldwide. Our commitment to high cGMP standards and quality compliance helped us maintain a strong track record in regulatory inspections with no critical observations. We have received cGMP approvals from over 25 international regulatory agencies, including those from US, EU, Japan, France, Brazil, Mexico, Turkey and GCC among others.
We have successfully commissioned our first overseas manufacturing facility at BioXcell, a biotechnology park in Johor, Malaysia. This greenfield integrated insulins manufacturing facility, one of Asia's largest, will cater to our global ambitions in the insulins space. The facility has received local cGMP certification from the National Pharmaceutical Control Bureau, Malaysia.
Generic Insulins Pipeline
Robust Biosimilars Portfolio
Biocon has among the largest and most diversified portfolios of biosimilars in advanced stages of development. Having made biosimilars available to patients in India and other emerging markets, Biocon is the first Indian company to launch biosimilar Insulin Glargine in Japan, one of the world's most stringently regulated markets. We will address the unfolding global biosimilars opportunity through a high-value portfolio comprises six biosimilars for oncology and autoimmune indications, three insulin analogs and generic rh-insulin. Collectively, these represent a global addressable market opportunity of over USD 70 billion at current reference product pricing. More importantly, the portfolio addresses many critical chronic diseases such as diabetes, cancer and autoimmune disorders. Biocon, in collaboration with its global partner Mylan, has made significant progress in advancing our key assets through global clinical trials. Overall, we are well positioned to be amongst the first wave of companies to address the biosimilars opportunity globally by leveraging our strong development capabilities, world-class manufacturing facilities, unblemished track record of quality compliance and strong global and regional partnerships.
Novel Assets Under Clinical Development
Credible Biopharma Innovator
We have leveraged our affordable innovation model to develop and commercialize novel therapies for cancer and autoimmune conditions. We have delivered to the Indian patient BIOMAb-EGFR™, a novel biologic for cancer, and ALZUMAb™(Itolizumab), our second novel biologic for treating chronic plaque psoriasis. We are now harnessing our capabilities in novel drug discovery research to advance an exciting oral insulin, Insulin Tregopil, through the clinics. We are also making progress on Itolizumab, the world's only clinically validated anti-CD6 targeting molecule, which we want to take to a global population. We are also exploring the breakthrough potential of immuno-oncology to develop patient-friendly therapies against malignant tumours. Our novel programs span a wide range of platforms and products from conventional peptides & MAbs to novel fusion MAbs and small interfering RNA (siRNA) based therapeutics.
We also providing integrated contract research and manufacturing services to leading global pharmaceutical and biotechnology companies through our subsidiary Syngene. With over 2,500 research scientists and a laboratory base over 900,000 square feet, Syngene services a diverse range of over 250 clients, including 8 of the Top 10 global pharma majors.
Consistent Value Creator
Biocon has been creating long-term value for its shareholders with the market capitalisation of the Company having multiplied almost four times since its debut on the bourses in 2004. Biocon was only the second Indian company to cross the USD 1 billion market capitalisation milestone on the first day of listing. In 2015, the successful IPO of Biocon's research services subsidiary Syngene unlocked immense value for shareholders. Syngene's market capitalization crossed the USD 1 billion mark within a week of listing.
Reputed Biotech Employer
We have built an employee-friendly environment for our gender-diverse workforce that is comparable to the best in the world. This has been validated by our position among the Top 20 Best Employers in the Biotech Industry as ranked by the prestigious Science magazine.
Conscientious Corporate Citizen
Our underlying ethos of access and affordability goes beyond our business. It represents the focus of the initiatives by Biocon Foundation, our Corporate Social Responsibility (CSR) wing. For over a decade now, Biocon Foundation has been promoting social and economic inclusion through healthcare, educational, and community development programs. These programs address the 'Right to Health', the 'Right to Education' and the 'Right to Sanitation' of the economically weaker sections of Indian society. WHO India recently recognized Biocon Foundation as a 'Public Health Champion' for providing sustainable solutions in the area of public health.
Biocon Academy spearheads our CSR initiatives in addressing the skill deficit in the Indian biotechnology industry by developing high-end talent through advanced learning and industrial training. Established as a Centre of Excellence for Advanced Learning in Biosciences in 2014, Biocon Academy leverages the rich industry experience of Biocon and subject matter expertise of international education partners such as Keck Graduate Institute of Claremont, California (US) to bridge the industry-academia gap.